Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
Recommended or optimised
836
Cancer Drugs Fund or Innovative Medicines Fund
64
Only in research
23
Not recommended
145
Terminated (no company submission)
177

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

Not recommended

145 appraisals, newest first, page 1 of 2
AppraisalMedicine pageNICE recommendationPublishedStatus
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
NICE TA1126
NatalizumabOptimised Not recommended28 Jan 2026Current
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
NICE TA1108
CemiplimabNot recommended5 Nov 2025Current
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments
NICE TA1091
TarlatamabNot recommended20 Aug 2025Current
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over
NICE TA1088
RuxolitinibNot recommended13 Aug 2025Current
Efgartigimod for treating antibody-positive generalised myasthenia gravis
NICE TA1069
EfgartigimodNot recommended4 Jun 2025Current
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over
NICE TA1050
—Not recommended26 Mar 2025Current
Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma
NICE TA1046
ZolbetuximabNot recommended12 Mar 2025Current
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites
NICE TA1045
—Optimised Not recommended5 Mar 2025
Updated 26 Aug 2026
Current
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over
NICE TA1033
—Not recommended12 Feb 2025Current
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
NICE TA992
Trastuzumab deruxtecanNot recommended29 Jul 2024Current
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma
NICE TA983
PembrolizumabNot recommended12 Jun 2024Current
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
NICE TA971
RemdesivirOptimised Not recommended8 May 2024Current
Dupilumab for treating moderate to severe prurigo nodularis
NICE TA955
DupilumabNot recommended13 Mar 2024Current
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments
NICE TA930
—Not recommended15 Nov 2023Current
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine
NICE TA928
CabozantinibNot recommended1 Nov 2023Current
Baricitinib for treating severe alopecia areata
NICE TA926
BaricitinibNot recommended25 Oct 2023Current
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer
NICE TA909
LorlatinibNot recommended12 Jul 2023Replaced by TA1103
Tixagevimab plus cilgavimab for preventing COVID-19
NICE TA900
—Not recommended14 Jun 2023Current
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma
NICE TA894
Axicabtagene CiloleucelNot recommended7 Jun 2023Current
Mosunetuzumab for treating relapsed or refractory follicular lymphoma
NICE TA892
MosunetuzumabNot recommended31 May 2023Current
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
NICE TA883
TafasitamabNot recommended3 May 2023Current
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments
NICE TA881
RipretinibNot recommended3 May 2023Current
Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19
NICE TA878
Nirmatrelvir, Sotrovimab, TocilizumabOptimised Recommended Not recommended29 Mar 2023
Updated 26 Feb 2026
Current
Esketamine nasal spray for treatment-resistant depression
NICE TA854
EsketamineNot recommended14 Dec 2022Current
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy
NICE TA850
AmivantamabNot recommended14 Dec 2022Current
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer
NICE TA831
OlaparibNot recommended5 Oct 2022Replaced by TA887
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer
NICE TA812
PralsetinibNot recommended3 Aug 2022Current
Ibrutinib for treating Waldenstrom’s macroglobulinaemia
NICE TA795
IbrutinibNot recommended8 Jun 2022Current
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea
NICE TA777
SolriamfetolNot recommended9 Mar 2022Current
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea
NICE TA776
PitolisantNot recommended9 Mar 2022Current
Fostamatinib for treating refractory chronic immune thrombocytopenia
NICE TA759
FostamatinibNot recommended7 Jan 2022Replaced by TA835
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer
NICE TA724
NivolumabNot recommended8 Sep 2021Current
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer
NICE TA721
Abiraterone acetateNot recommended18 Aug 2021Replaced by TA1110
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
NICE TA715
Adalimumab, Etanercept, Infliximab, AbataceptOptimised Not recommended14 Jul 2021Current
Ozanimod for treating relapsing–remitting multiple sclerosis
NICE TA706
OzanimodNot recommended9 Jun 2021Current
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy
NICE TA696
—Not recommended12 May 2021Replaced by TA984
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA692
PembrolizumabNot recommended28 Apr 2021Current
Selective internal radiation therapies for treating hepatocellular carcinoma
NICE TA688
—Optimised Not recommended31 Mar 2021
Updated 3 Jul 2024
Current
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies
NICE TA669
—Not recommended27 Jan 2021Replaced by TA852
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma
NICE TA650
PembrolizumabNot recommended30 Sep 2020Current
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
NICE TA621
OsimertinibNot recommended22 Jan 2020Current
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy
NICE TA613
—Not recommended20 Nov 2019Replaced by TA953
Idelalisib for treating refractory follicular lymphoma
NICE TA604
IdelalisibNot recommended2 Oct 2019Current
Enzalutamide for hormone-relapsed non-metastatic prostate cancer
NICE TA580
EnzalutamideNot recommended15 May 2019Current
Cochlear implants for children and adults with severe to profound deafness
NICE TA566
—Recommended Optimised Not recommended7 Mar 2019Current
Darvadstrocel for treating complex perianal fistulas in Crohn’s disease
NICE TA556
—Not recommended9 Jan 2019Current
Vandetanib for treating medullary thyroid cancer
NICE TA550
VandetanibNot recommended12 Dec 2018Current
Padeliporfin for untreated localised prostate cancer
NICE TA546
—Not recommended21 Nov 2018Current
Cenegermin for treating neurotrophic keratitis
NICE TA532
CenegerminNot recommended18 Jul 2018Current
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
NICE TA530
NivolumabNot recommended4 Jul 2018Current
Beta interferons and glatiramer acetate for treating multiple sclerosis
NICE TA527
—Recommended Not recommended27 Jun 2018Current
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
NICE TA515
EribulinNot recommended28 Mar 2018Current
Regorafenib for previously treated advanced hepatocellular carcinoma
NICE TA514
RegorafenibNot recommended21 Mar 2018Current
Lesinurad for treating chronic hyperuricaemia in people with gout
NICE TA506
—Not recommended7 Feb 2018Current
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
NICE TA503
FulvestrantNot recommended31 Jan 2018Current
Naltrexone–bupropion for managing overweight and obesity
NICE TA494
Naltrexone, BupropionNot recommended12 Dec 2017Current
Vismodegib for treating basal cell carcinoma
NICE TA489
VismodegibNot recommended22 Nov 2017Current
Immunosuppressive therapy for kidney transplant in children and young people
NICE TA482
Basiliximab, Mycophenolate Mofetil, Tacrolimus, Sirolimus, Everolimus, BelataceptRecommended Not recommended11 Oct 2017Current
Immunosuppressive therapy for kidney transplant in adults
NICE TA481
Basiliximab, Mycophenolate Mofetil, Tacrolimus, Sirolimus, Everolimus, BelataceptRecommended Not recommended11 Oct 2017Current
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
NICE TA440
—Not recommended26 Apr 2017Current
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA425
Dasatinib, Nilotinib, ImatinibOptimised Recommended Not recommended21 Dec 2016Current
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
NICE TA414
CobimetinibNot recommended26 Oct 2016Current
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
NICE TA411
NecitumumabNot recommended28 Sep 2016Current
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
NICE TA403
RamucirumabNot recommended24 Aug 2016Current
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
NICE TA399
AzacitidineNot recommended27 Jul 2016Current
Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
NICE TA398
IvacaftorNot recommended27 Jul 2016Current
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
NICE TA389
Paclitaxel, Pegylated liposomal doxorubicin, Gemcitabine, Trabectedin, TopotecanRecommended Not recommended27 Apr 2016Current
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
NICE TA378
—Not recommended27 Jan 2016Current
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
NICE TA374
Erlotinib, GefitinibOptimised Not recommended16 Dec 2015Current
Apremilast for treating active psoriatic arthritis
NICE TA372
—Not recommended16 Dec 2015Replaced by TA433
Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane
NICE TA371
Trastuzumab emtansineNot recommended16 Dec 2015Current
Apremilast for treating moderate to severe plaque psoriasis
NICE TA368
ApremilastNot recommended25 Nov 2015Current
Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer
NICE TA360
—Not recommended28 Oct 2015Current
Everolimus for preventing organ rejection in liver transplantation
NICE TA348
EverolimusNot recommended22 Jul 2015Current
Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib
NICE TA338
PomalidomideNot recommended25 Mar 2015Current
Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer
NICE TA332
—Not recommended23 Feb 2015Current
Ustekinumab for treating active psoriatic arthritis
NICE TA313
—Not recommended27 May 2014Replaced by TA340
Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer
NICE TA309
PemetrexedNot recommended23 Apr 2014Replaced by TA402
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
NICE TA307
AfliberceptNot recommended25 Mar 2014Current
Bosutinib for previously treated chronic myeloid leukaemia
NICE TA299
BosutinibNot recommended27 Nov 2013Replaced by TA401
Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene
NICE TA296
CrizotinibNot recommended25 Sep 2013Current
Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy
NICE TA295
EverolimusNot recommended28 Aug 2013Current
Pegloticase for treating severe debilitating chronic tophaceous gout
NICE TA291
—Not recommended26 Jun 2013Current
Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis
NICE TA289
RuxolitinibNot recommended26 Jun 2013Replaced by TA386
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
NICE TA285
BevacizumabNot recommended22 May 2013Current
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
NICE TA284
BevacizumabNot recommended22 May 2013Current
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract
NICE TA272
VinflunineNot recommended23 Jan 2013Current
Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy
NICE TA271
—Not recommended23 Jan 2013Replaced by TA301
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
NICE TA265
DenosumabRecommended Not recommended24 Oct 2012Current
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
NICE TA263
BevacizumabNot recommended22 Aug 2012Current
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2
NICE TA257
Lapatinib, TrastuzumabNot recommended27 Jun 2012Current
Cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen
NICE TA255
CabazitaxelNot recommended11 May 2012Replaced by TA391
Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia
NICE TA251
Imatinib, Nilotinib, DasatinibRecommended Not recommended25 Apr 2012Current
Eribulin for the treatment of locally advanced or metastatic breast cancer
NICE TA250
EribulinNot recommended3 Apr 2012Replaced by TA423
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
NICE TA242
Cetuximab, Bevacizumab, PanitumumabNot recommended25 Jan 2012Current
Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance
NICE TA241
Nilotinib, DasatinibRecommended Not recommended13 Jan 2012Current
Fulvestrant for the treatment of locally advanced or metastatic breast cancer
NICE TA239
FulvestrantNot recommended14 Dec 2011Current
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
NICE TA238
TocilizumabRecommended Not recommended14 Dec 2011Current
Ranibizumab for the treatment of diabetic macular oedema
NICE TA237
RanibizumabNot recommended30 Nov 2011Replaced by TA274
Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs
NICE TA234
AbataceptNot recommended24 Aug 2011Replaced by TA280

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.